收录解读
现有结构预测网络基于共进化统计,在蛋白质药物发现中表现优异,但对含非规范残基、大环化和复杂拓扑的肽治疗剂准确性不足,而肽类药物正成为重要模态。
本文提出Vilya-2,一个基于扩散Transformer的模型,扩展了Vilya-1的全原子表示,从单分子建模转向分子与蛋白质靶标的相互作用建模,实现不同分子类型间的迁移学习。
Vilya-2在肽-蛋白界面预测中,59.1%的界面主链RMSD低于2Å,远超现有共折叠模型;在小分子对接上达到最先进水平,并泛化到训练中未见的新型复合物、大环化合物和更大尺度的二硫键交联微蛋白。
PDF显示其在肽、小分子、大环和微蛋白上形成统一全原子建模能力,并开放Riptides基准代码;但模型权重未公开,尚不足以重定义整个结构生物学范式。
原始摘要
Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 {\AA} backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.